Adding radiotherapy boosts prostate cancer survival

LONDON - Adding radiotherapy to hormone drugs for prostate cancer patients significantly improves survival compared with hormone treatment alone, and the combination could save many lives if it were made standard practice, scientists said on Thursday.
In a study of men with prostate cancer - the second most common form of cancer among men worldwide - researchers found that 74 percent of those given radiotherapy plus hormone treatment were still alive after seven years.
This compared with 66 percent who got hormone drugs but did not receive radiotherapy, the researchers said.
"The results of this trial are extremely encouraging," said Matthew Sydes, senior scientist at Britain's Medical Research Council's Clinical Trials Unit, which helped conduct the study.